Title: Roche is looking for a COVID-19 HEOR collaboration.
Submitted by: Ursula Becker, HTA Strategy Lead, Roche ( ursula.becker@roche.com)

"As you might have heard, Roche is at the moment running several clinical trials for tocilizumab (Actemra) in COVID19 patients ( https://www.roche.com/media/releases/med-cor-2020-03-19.htm)
Within our HTA Evidence group we have started working on a global cost effectiveness model for Actemra in this indication. For the development of this model we are looking for international scientific collaborator(s).

  • Do you have a sound experience in economic models?
  • Have you already worked on COVID19 and have some great ideas on how to model this disease?

If so, please contact us, explaining briefly your background and your motivation.
(for information contact directly Ursula Becker in the above email address)

Title: COVID-19 Impact Survey

Submitted by: Nuria Oliver (nuriaoliver@outlook.com)

Spain has been one of the most impacted countries by the COVID-19 pandemic. Since the first confirmed case of COVID-19 reported on January 31st, 2020, over 240,000 cases have been reported, resulting in over 27,000 deaths. The economic and social impact of the COVID-19 pandemic is without precedent. In this context, it is of paramount importance to quickly assess the situation and perception of citizens during the pandemic. To quickly assess the Spanish citizens’ situation and perception during the COVID-19 pandemic, on March 28th, 2020 we launched the Covid19impactsurvey. The survey became viral in the 44 hours since its deployment, such that we collected over 140,000 answers. Today, with over 233,000 answers has become the largest COVID-19 citizens’ survey in Spain. Via 25 questions, the survey collects information about people’s social contact behavior during the confinement, their personal economic impact, their workplace situation, their health status and the emotional impact of the confinement. It has been tremendously useful to shed light on these important topics and its results have helped the Valencian Government make better, more evidence-driven decisions. 

Results of the analysis of the first wave of answers (over 150,000) can be found here: https://arxiv.org/abs/2004.01014 and all the answers to date can be seen here: https://covid19impactsurvey.org/results

The survey has been extensively featured in the Spanish media and was recently featured in MSNBC https://www.youtube.com/watch?feature=youtu.be&v=A06j9Nv8-CA


Title: Response to COVID-19 Crisis in Italy
Submitted by: Rossella Di Bidino. Health Technologies, Policlinico Gemelli, Rome (rossella.dibidino@policlinicogemelli.it)

Since March 2020 Altems- Graduate School of Health Economics and Management (Alta Scuola Di Economia E Management Dei Sistemi Sanitari) was monitoring the COVID-19 situation across Italy seeking to provide an economic organizational perspective on actual management of COVID-19 at national and local level. A renowned group of researchers have collected and curated a series of reports that could be accessed here: https://altems.unicatt.it/altems-covid-19



Title: Information platform about medicines and COVID-19: new launch of The State Expert Center of the Ministry of Health of Ukraine
Submitted by: Oresta Piniazhko, Director of HTA Department of SEC of Ministry of Health of Ukraine (orestapb@gmail.com)

The State Expert Center of the Ministry of Health of Ukraine has launched a special project - an official information resource which informs about the medicines that are currently used in the prevention and treatment of COVID-19.
The project was created to disseminate reliable information, systematized by experts of HTA Department based on  recommendations of WHO, ECDC, CDC and official governmental and regulatory agencies publications, including FDA, EMA, as well as national clinical guidelines and treatment protocols. Currently, the information resource covers these main topics: Antiseptics, antipyretics (ibuprofen, paracetamol, acetylsalicylic acid), antivirals (remdesivir, lopinavir/ritonavir, favipiravir), medicines that affect the immune response (tocilizumab, hydroxychloroquine, Intravenous immunoglobulin (IVIG)), antibiotics and medicines for non-communicable diseases (treatment of diabetes, cardiovascular disease, oncology and COVID-19). The list could be accessed here: www.covid19.dec.gov.ua

Title: Acumen Health Research Institute (AHRI) COVID-19 activities
Submitted by: Amy Morlock, Managing Director (amorloc1@acumenhealthresearch.org)

AHRI is a 501c3 non-profit research group that collects monthly population level health data on US adults using a representative web-based survey. AHRI quickly adapted their platform to study the impact of COVID.
The objective of the study was to better understand the rate of COVID cases, and the impact of COVID on mental and physical health, resource utilization, and productivity for the following:

  • Adults who reported having COVID and tested positive/negative
  • Adults who suspect having COVID without test confirmation
  • Adults who do not suspect they have or have had COVID

Data has been collected on a representative sample of over 6,000 US adults. An initial review of the sample characteristics shows the data is representative of the US population. Having a validated platform to collect representative data allows researchers to address questions of interest quickly and provides insights into the real world that are not captured in the subset of patients being captured and reported by the health system. Questions that will be able to be addressed include: testing rates, symptoms, impact on HRQoL, productivity, disparities in care and resource utilization as well as where there is and is not agreement with state level plans to re-open the economy.
To learn more about the COVID Study or AHRI, visit www.acumenhealthresearch.org; or info@acumenhealthresearch.org.

Title: Clinerion COVID-19 Report
Submitted by Douglas Drake, Director Client Solutions. douglas.drake@clinerion.com

Clinerion is a Switzerland-based digital healthcare company focused on EMR technology, and with a patient network of over 73.4 million in 20 countriess. Clinerion wants to enable better healthcare and patient metrics through our network, technology and hospital relationships.
Clinerion launched a recent COVID19 report from the Clinerion PNEx network as example of efforts relative to COVID19 coverage and patient metrics. If you want to access to the report click here, and for more information about Clinerion, please see their website: www.clinerion.com

Title: Registry to study factors that may impact COVID-19 occurrence and severity
 Submitted by: Nancy Dreyer, Chief Science Officer (Nancy.dreyer@iqvia.com)

IQVIA COVID Active Research Experience (CARE) Project is a community-driven reporting program for adults who suspect or know they have been exposed to COVID-19. The objective is to identify factors that may prevent symptom onset or reduce the severity of infections. Participants report symptoms, medication use, test results and other information, and are asked to consent to follow-up over three months. Alternate contacts are requested to help ascertain health status if the participant cannot respond for themselves.
The website includes near real-time summaries of the >19,000 patients enrolled in the registry (as of 5/14/20).  
Please visit CARE website: www.helpstopCOVID19.com and share it  with anyone that thinks they have been affected by COVID-19


ISPOR’s COVID-19 news pages are being made available in response to the global COVID-19 crisis. Provided content is not managed by nor endorsed by ISPOR.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now